182 CMAAO
CORONA FACTS and MYTH Human Challenge
Dr K
Aggarwal
President
CMAAO
With inputs
from Dr Monica Vasudev
1048: New guidance from the UK National
Diabetes COVID-19 Response Group: August 2 in Diabetic Medicine
1. Triple insult of
dexamethasone-induced impaired glucose metabolism, COVID-19-induced insulin
resistance, and COVID-19 impaired insulin production.
2. Randomised Evaluation of COVID-19 Therapy
(RECOVERY) trial showed that dexamethasone reduced deaths in patients with
COVID-19 on ventilators or receiving oxygen therapy. The dose used in RECOVERY
— 6 mg daily for 10 days — is five- to six-fold greater than the therapeutic
glucocorticoid replacement dose.
3. High glucocorticoid doses can exacerbate hyperglycaemia
in people with established diabetes, unmask undiagnosed diabetes, precipitate hyperglycaemia
or new-onset diabetes, and can also cause hyperglycaemic hyperosmolar state
(HHS).
4. The guidance recommends a target glucose of
108-180 mg/dL and up to 216 mg/dL is "acceptable."
5. Use of once- or twice-daily NPH insulin is recommended for
patients whose glucose has risen above 216 in some cases with the addition of a
long-acting analog.
6. The guidance says that patients already taking
premixed insulin formulations can continue using them while increasing the dose
by 20% to 40%.
7. Given the risk of hypoglycaemia associated
with those formulations, many experts say they would switch those patients to
NPH during the time that they're on dexamethasone.
Comments
1. Steroid induced high sugar is often
post meals.
2. Give repaglinide 1 mg or 2 mg
sublingual before meals
3. Add 0.3 units insulin per kg in
divided doses
4. In high risk cases steroids may have
to be started on day 1 itself so adjust dose accordingly
5. In post Covid illness steroids may
have to continue for weeks together like in any immunological illness
No comments:
Post a Comment